**Figure S1.** Patient disposition.

****

aAll patients who were enrolled in the study and had one or more sample evaluated with a valid result for immunogenicity (full analysis set). Reasons for withdrawal included request to use a portacath, participation in another study testing the same antibodies, family participation in another Sarepta Therapeutics, Inc. study that does antibody tests, lost to follow-up, resourcing issues, and inability to obtain consent after two blood draws.

**Table S1.** Seroprevalence of anti-rAAVrh74 antibody titers in the overall population by age group and by antibody titer range (full analysis set).

|  |  |
| --- | --- |
| Overall (*N*=101) | *n* (%) |
| Positive, n (%)  95% CI | 14 (13.9)  (7.8–22.2) |
| **Range of anti-rAAVrh74 antibody titers (*N*=101)** | ***n* (%)** |
| <1:400 | 87 (86.1) |
| 1:400 | 1 (1.0) |
| 1:800 | 4 (4.0) |
| 1:1600 | 6 (5.9) |
| 1:3200 | 3 (3.0) |

CI, confidence interval; rAAVrh74, recombinant adeno-associated virus serotype rh74.